Journal ArticleOPEN ACCESS

Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months

ACS Central Science (2023) 9(5) 849-857
DOI: 10.1021/acscentsci.3c00145
36Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The advancement of nirmatrelvir, the active ingredient in Paxlovid, from discovery to emergency use authorization was achieved in just 17 months, requiring an unprecedented rate of chemical process development.

Cite

CITATION STYLE

APA

Allais, C., Connor, C. G., Do, N. M., Kulkarni, S., Lee, J. W., Lee, T., … Weekly, R. M. (2023). Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months. ACS Central Science, 9(5), 849–857. https://doi.org/10.1021/acscentsci.3c00145

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free